SCHEMBL186344

SCHEMBL186344

C#CCOc1c(Cl)cccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAOB P27338 3/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2A6 P11509 1/20 0.38
CCR4 P51679 1/20 0.37
HPGD P15428 2/20 0.37
TSHR P16473 1/20 0.37
GSTP1 P09211 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5251072 0.80 KMT2A (0.52) KMT2AL3MBTL1POLBCYP2A6HPGD
SCHEMBL3805546 0.80 HTT (0.45) KMT2ALMNAHTTPOLBMAPK1
SCHEMBL16395567 0.78 HTT (0.38) KMT2ALMNAHTTPOLBMAPK1
SCHEMBL8225537 0.78 L3MBTL1 (0.46) KMT2ALMNAL3MBTL1HTTHPGD
SCHEMBL3198497 0.77 CYP3A4 (0.49) LMNAPOLBMAPK1HSD17B10MAOB
SCHEMBL20541067 0.77 CYP3A4 (0.46) LMNAHTTMAOBCYP3A4CYP2A6
SCHEMBL16395177 0.77 GSTP1 (0.38) KMT2ALMNAHTTPOLBMAPK1
SCHEMBL15747178 0.76 SCN4A (0.47) LMNAL3MBTL1MAOBCYP3A4TSHR
SCHEMBL5981851 0.76 MAPT (0.50) KMT2ALMNAL3MBTL1HTTMAOB
SCHEMBL17282973 0.76 NPC1 (0.38) POLBMAPK1HSD17B10MAOBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3242878-B1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD (IN) 2020-10-14 EP disclosed
EP-3242878-B1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD (IN) 2020-10-14 EP disclosed
US-10435402-B2 Bicyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2019-10-08 US disclosed
US-10435402-B2 Bicyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2019-10-08 US disclosed
US-20170362225-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2017-12-21 US disclosed
US-20170362225-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2017-12-21 US disclosed
US-20170362225-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2017-12-21 US disclosed
EP-3242878-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2017-11-15 EP disclosed
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-08-25 US disclosed
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS THE SCRIPPS RESEARCH INSTITUTE (US) 2016-08-25 US disclosed
US-20100234415-A1 INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-09-16 US disclosed
WO-2010099039-A1 INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-09-02 WO disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed
EP-1192170-B1 PROPARGYL PHENYL ETHER A2A RECEPTOR AGONISTS CV THERAPEUTICS INC (US) 2003-05-14 EP disclosed
EP-1192170-A1 PROPARGYL PHENYL ETHER A2A RECEPTOR AGONISTS CV THERAPEUTICS, INC. (US) 2002-04-03 EP disclosed
US-6180615-B1 STIMULATE MAMMALIAN CORONARY VASODILATATION FOR THERAPEUTIC PURPOSES AND FOR PURPOSES OF IMAGING THE HEART CV THERAPEUTICS, INC. 2001-01-30 US disclosed
WO-2000078777-A1 PROPARGYL PHENYL ETHER A2A RECEPTOR AGONISTS CV THERAPEUTICS, INC. (US) 2000-12-28 WO disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362225-A1 BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF RORC, RORA, RORB KMT2A 4147/4885LMNA 730/4885L3MBTL1 3516/4885
US-20160244435-A1 EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS NQO1, TXN2, MPO KMT2A 4713/4885LMNA 2408/4885L3MBTL1 3421/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 KMT2A 1399/4885LMNA 3167/4885L3MBTL1 2812/4885
US-20100234415-A1 INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS PTGER2, PTGDR2, PTGDR KMT2A 3242/4885LMNA 4369/4885L3MBTL1 4542/4885
US-10435402-B2 Bicyclic compounds, compositions and medicinal applications thereof RORA, RORB, RORC KMT2A 4064/4885LMNA 502/4885L3MBTL1 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.